menu
    • menu
    [{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"AN0025","moa":"EP4","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Merck","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Merck"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Paclitaxel","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adlai Nortye \/ Oncolytics Biotech","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Oncolytics Biotech"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Xiamen Biotime Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"AN4005","moa":"PD-L1","graph1":"Oncology","graph2":"Phase I","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Adlai Nortye \/ Adlai Nortye Ltd.","highestDevelopmentStatusID":"6","companyTruncated":"Adlai Nortye \/ Adlai Nortye Ltd."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Oncolytics Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Avelumab","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adlai Nortye \/ Adlai Nortye","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Adlai Nortye"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Nucleai","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Buparlisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Nucleai","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Nucleai"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.11,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Cantor Fitzgerald & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Public Offering","leadProduct":"Buparlisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Cantor Fitzgerald & Co.","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Cantor Fitzgerald & Co."},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Buparlisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Adlai Nortye \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Adlai Nortye \/ Not Applicable"},{"orgOrder":0,"company":"Adlai Nortye","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Palupiprant","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Adlai Nortye","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Adlai Nortye \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Adlai Nortye \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Adlai Nortye

    Menu

    Adlai Nortye

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Palupiprant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Adlai Nortye Doses First Patient in Phase II Trial of Palupiprant for Rectal Cancer

                            Details : AN0025 is a small molecule prostaglandin E receptor 4 antagonist, which is being in the phase II clinical trials studies for the treatment of locally advanced rectal cancer.

                            Brand Name : AN0025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 22, 2024

                            Lead Product(s) : Palupiprant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN20...

                            Details : AN2025 (buparlisib ) is an oral pan-PI3K inhibitor, It is being evaluated in combination with paclitaxel for the treatment of recurrent or metastatic head and neck squamous cell carcinoma.

                            Brand Name : AN2025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 17, 2023

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $57.5 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Adlai Nortye Ltd. Announces Closing of Initial Public Offering

                            Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...

                            Brand Name : AN2025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 03, 2023

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $57.5 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $106.1 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Adlai Nortye Ltd. Announces Pricing of Initial Public Offering

                            Details : The net proceeds will fund the ongoing registrational trial for AN2025 (buparlisib), an oral pan-PI3K inhibitor that targets all class I PI3K isoforms, the milestone payments in connection with development of AN2025 and the commercial launch, if approved...

                            Brand Name : AN2025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 29, 2023

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Cantor Fitzgerald & Co.

                            Deal Size : $106.1 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Nucleai

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trial...

                            Details : The collaboration aims to focus on identifying subjects that could derive benefit from AN2025 (buparlisib) treatment in metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN) patients and will expand to other indications and clinical trials.

                            Brand Name : AN2025

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 31, 2023

                            Lead Product(s) : Buparlisib,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Nucleai

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelareorep,Paclitaxel,Avelumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Oncolytics Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination...

                            Details : In IND-213, HR+/HER2- breast cancer patients treated with Reolysin (pelareorep) and paclitaxel showed a statistically significant, near doubling of overall survival compared to those treated with paclitaxel alone.

                            Brand Name : Reolysin

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 24, 2022

                            Lead Product(s) : Pelareorep,Paclitaxel,Avelumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Oncolytics Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AN4005

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Xiamen Biotime Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Adlai Nortye Announces Global License-out Agreement with Biotime for Several Products Including PD-L1 Inhibito...

                            Details : This includes the rights and interests of Adlai Nortye in the development, manufacturing and commercialization of AN4005 and AN3025 in Greater China, and AN1005, AN6015 and AN9015 worldwide.

                            Brand Name : AN4005

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 26, 2022

                            Lead Product(s) : AN4005

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Xiamen Biotime Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pelareorep,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Oncolytics Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Oncolytics Biotech®Partner Adlai Nortye Doses First Patient in Chinese Bridging Trial Evaluating Pelareorep-P...

                            Details : BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor used in Chinese patients with advanced or metastatic breast cancer.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 14, 2021

                            Lead Product(s) : Pelareorep,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Oncolytics Biotech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed

                            Adlai Nortye

                            China arrow
                            Cosmoprof
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AN0025,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Adlai Nortye Doses First Patient in Phase 1b Clinical Trial of AN0025 in Combination with Merck's KEYTRUDA for...

                            Details : First patient has been dosed in a phase 1b clinical trial (AN0025S0103) to evaluate AN0025, an investigational, potentially first in class oral EP4 antagonist, in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with locally advanced/metas...

                            Brand Name : AN0025

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 24, 2020

                            Lead Product(s) : AN0025,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck & Co

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth